SILKIS

This brand name is authorized in Canada, Finland, France, Hong Kong SAR China, Ireland, Netherlands, Singapore, Spain, UK.

Active ingredients

The drug SILKIS contains one active pharmaceutical ingredient (API):

1	Calcitriol UNII FXC9231JVH - CALCITRIOL
	Calcitriol is the most active known form of vitamin D3 in stimulating intestinal calcium transport. In physiological amounts it augments the intestinal absorption of calcium and phosphate and plays a significant part in the regulation of bone mineralisation.
	Read more about Calcitriol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SILKIS Ointment	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D05AX03	Calcitriol	D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use
Discover more medicines within D05AX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02338572
ES	Centro de información online de medicamentos de la AEMPS	64527
FI	Lääkealan turvallisuus- ja kehittämiskeskus	592147
FR	Base de données publique des médicaments	62597239
GB	Medicines & Healthcare Products Regulatory Agency	26686
HK	Department of Health Drug Office	50580
IE	Health Products Regulatory Authority	45913
NL	Z-Index G-Standaard	14554747
NL	Z-Index G-Standaard, PRK	56014
SG	Health Sciences Authority	12160P